Novo Nordisk A/S (NOVO-B.CO) analysis

Loading the Vaultflake…

Health is the lab's cash, not the hospital's. Quality separates the diabetes sale, which repeats, from a year of heavy obesity demand that may not. Growth follows patients and the price the payer accepts, not a factory described here. P/E is read against a year of shortage or heavy demand, not against that year as normal. Shareholder return, if any, has to fit after development. Do not call it the most valuable European company.

The P/E of a year of heavy demand is not the earnings if the payer squeezes the price. EV/EBITDA is read without treating idle capacity as a cost that does not return. Do not use Eli Lilly's multiple as if the two portfolios were the same book. A dash if NOVO-B.CO is missing.

Limits of this report

Not advice on Novo Nordisk. Vaultflake does not describe manufacturing or administration, and does not treat the patent as exclusive. Read the filings. The table is a snapshot, not a target price.

Questions from this report